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Connexin40 regulates platelet function
Sakthivel Vaiyapuri1, Leonardo A. Moraes1, Tanya Sage1, Marfoua S. Ali1, Kirsty R. Lewis1,
Martyn P. Mahaut-Smith2, Ernesto Oviedo-Orta3, Alexander M. Simon4 & Jonathan M. Gibbins1
The presence of multiple connexins was recently demonstrated in platelets, with notable
expression of Cx37. Studies with Cx37-deﬁcient mice and connexin inhibitors established
roles for hemichannels and gap junctions in platelet function. It was uncertain, however,
whether Cx37 functions alone or in collaboration with other family members through
heteromeric interactions in regulation of platelet function. Here we report the presence and
functions of an additional platelet connexin, Cx40. Inhibition of Cx40 in human platelets or its
deletion in mice reduces platelet aggregation, ﬁbrinogen binding, granule secretion and clot
retraction. The effects of the Cx37 inhibitor 37,43Gap27 on Cx40 / mouse platelets and of
the Cx40 inhibitor 40Gap27 on Cx37 / mouse platelets revealed that each connexin is able
to function independently. Inhibition or deletion of Cx40 reduces haemostatic responses in
mice, indicating the physiological importance of this protein in platelets. We conclude
that multiple connexins are involved in regulating platelet function, thereby contributing to
haemostasis and thrombosis.
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C
onnexins are a family of membrane proteins that assemble
into connexons or hemichannels on the plasma mem-
brane by oligomerization of six connexin monomers1.
Hemichannels facilitate the transport of small molecules (up to
B1,000Da) between the interior and exterior of isolated cells2,3
and form gap junctions on docking of connexons between
adjacent cells, allowing direct intercellular communication1.
Over 20 connexins have been identiﬁed in various mammalian
cell types, which are capable of forming homomeric (that is
comprising a single connexin type) or heteromeric (that is
comprising more than one connexin type) hemichannels and
gap junctions with varying conductance properties4–8. Gap
junction-mediated intercellular communication has vital
roles in several cell types and tissues such as nerve cells9, bone
marrow stromal cells10, oocytes11 and cardiac muscle12,
and recent studies have identiﬁed roles for connexins in
circulating cells such as monocytes13, T-cells14,15 and
platelets16,17.
Platelets aggregate on vessel wall damage to prevent bleeding at
the site of injury18. We recently reported17 the presence of multiple
connexins in platelets with notable expression of Cx37. The study
demonstrated gap junction-dependent intercellular communication
between platelets and a role for connexin hemichannels and gap
junctions in platelet function17. Gap junction blockers such as
carbenoxolone, 18b-glycyrrhetinic acid and 37,43Gap27 (refs 19,20),
with varying selectivity, reduced a range of platelet functions
including aggregation and clot retraction17. It is uncertain,
however, whether other connexin family members are involved,
and a recent study suggested Cx37 alone to be present and
functional in platelets16. Given the possibility of heteromeric
hemichannel formation, these connexins may depend on each
other to elicit their functions. In this report we demonstrate the
presence of another vascular connexin, Cx40, in platelets. We show
that Cx40 and Cx37 are able to function independently of each
other in platelets, and establish that multiple connexin family
members contribute to the promotion of haemostasis.
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Figure 1 | Presence of Cx40 and effects of its inhibition on platelet function. (a) Presence of Cx40 in human platelets was conﬁrmed by immunoblot
analysis (human umbilical vascular endothelial cells (a), and resting (b) or CRP-XL- (1mgml 1) stimulated human platelets (c)). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was detected as a loading control. Human platelet aggregation performed in the presence or absence of 40Gap27 was
recorded for 90 s following stimulation with 0.5 (b,c) or 1mgml 1 (d,e) CRP-XL (a scrambled peptide control showed no effect on aggregation compared
with the vehicle (f,g)), 0.1 Uml 1 thrombin (h,i) and 10 mM ADP (j,k). Cumulative data represent mean±s.d. (n¼4). The level of aggregation obtained
with vehicle was taken as 100% (Student’s t-test, *Po0.05 and **Po0.01).
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Results
Inhibition of Cx40 reduces platelet activation. Transcriptomic
analysis revealed Cx40 to be expressed in megakaryocytes17. In the
present study we conﬁrmed the presence of Cx40 protein in human
platelets (Fig. 1a and Supplementary Fig. S1), the levels of which
were unaltered following stimulation of platelets with a glycoprotein
(GP) VI-selective (collagen receptor) ligand, cross-linked collagen-
related peptide (CRP-XL). The effect of 40Gap27 (ref. 19), a selective
Cx40 mimetic peptide inhibitor (this peptide comprises an 11-
amino-acid residue sequence mimicking a region of extracellular
loop and that can competitively prevent gap-junction formation or
interfere with hemichannel function) on human platelet aggregation
was explored. Washed human platelets were stimulated with CRP-
XL in the presence of increasing concentrations of 40Gap27.
Aggregation induced by CRP-XL (0.5mgml 1) was reduced by
B50%, 35% and 15% at 100, 50 and 10mgml 1 of 40Gap27,
respectively (Fig. 1b,c). The reduction in aggregation was less pro-
nounced (20% inhibition with 100mgml 1 of 40Gap27) when a
higher CRP-XL concentration (1mgml 1) was used (Fig. 1d,e). A
scrambled peptide control for 40Gap27 showed no effect (Fig. 1f,g).
Cx40 involvement in the regulation of platelet function was not
restricted to GPVI-mediated activation, as thrombin- (0.1Uml 1;
Fig. 1h,i) and ADP- (10mM; Fig. 1j,k) induced aggregation was
also inhibited by 40Gap27. This is consistent with the inability of
connexins to modulate GPVI-proximal signalling events17.
Deletion of Cx40 reduces platelet activation. To further assess
the importance of Cx40 in platelet function, Cx40 / mouse
platelets were examined. Immunoblot analysis conﬁrmed the
absence of Cx40 in platelets (Fig. 2a). To exclude compensatory
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Figure 2 | Deletion of Cx40 affects platelet activation. Deletion of Cx40 was conﬁrmed in Cx40 / mouse platelets by immunoblotting (a). The
expression of Cx32 (b), Cx37 (c) and Cx43 (d) were analysed by immunoblot analysis using Cx40þ /þ and Cx40 / mouse platelets. 14-3-3z was
detected as a loading control. Blots are representative of four separate experiments. The expression levels of aIIbb3 (e), a2b1 (f), GPVI (g) and GPIba
(h) were analysed on Cx40þ /þ and Cx40 / mouse platelets by ﬂow cytometry. Platelet aggregation performed in the presence or absence of 40Gap27
using washed platelets obtained from Cx40þ /þ (i) and Cx40 / (j) mice was recorded for 180 s following stimulation with CRP-XL (0.5mgml 1).
The level of aggregation obtained in the absence of 40Gap27 was taken as 100%. Similar aggregations were performed using washed platelets obtained
from Cx40þ /þ and Cx40 / mice following stimulation with 0.5 (k,l) or 1mgml 1 CRP-XL (m,n). Data represent mean±s.d. (n¼4). The level of
aggregation obtained with Cx40þ /þ was taken as 100% (Student’s t-test, *Po0.05 and **Po0.01).
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effects of Cx40 deletion on expression of other family members,
the levels of other platelet connexins, such as Cx32 (Fig. 2b), Cx37
(Fig. 2c) and Cx43 (Fig. 2d), were analysed in Cx40 / platelets
by immunoblot analysis and were indistinguishable from those in
Cx40þ /þ platelets. Expression levels of platelet receptors:
integrins aIIbb3 (Fig. 2e), a2b1 (Fig. 2f), GPVI (Fig. 2g) and GPIb
(Fig. 2h) on Cx40 / and Cx40þ /þ platelets were found to be
similar. 40Gap27 (100 mgml 1) inhibited CRP-XL- (0.5 mgml 1)
stimulated mouse (Cx40þ /þ ) platelet aggregation by B30%
(Fig. 2i) but exhibited no inhibitory effects on Cx40 / platelets
(Fig. 2j), conﬁrming inhibitor selectivity. CRP-XL- (0.5 mgml 1)
induced aggregation was reduced by around 50% in Cx40 /
platelets compared with Cx40þ /þ platelets (Fig. 2k,l),
with slightly less-pronounced inhibition (30% inhibition) at
higher agonist concentrations (for example, 1mgml 1 CRP-XL;
Fig. 2m,n).
Cx40 modulates inside-out signalling to integrin aIIbb3. The
inhibition of platelet aggregation in response to 1mgml 1 CRP-
XL following Cx40 blockade was accompanied by reduced ﬁbri-
nogen binding (60% decrease with 100mgml 1 of 40Gap27),
indicating the involvement of this connexin in platelet inside-out
signalling to integrin aIIbb3 (Fig. 3a). The inhibitory effects of
40Gap27 were also observed when human platelets were stimu-
lated with ADP (10mM; Fig. 3b) or thrombin (0.1Uml 1;
Fig. 3c). Similarly, ﬁbrinogen binding to CRP-XL- (1mgml 1)
stimulated mouse platelets in whole blood was reduced byB50%
in Cx40 / platelets compared with Cx40þ /þ platelets (Fig. 3d).
Inhibition or deletion of Cx40 affects platelet secretion. The
level of P-selectin exposed on the surface of platelets (a marker
for a-granule secretion) following stimulation with CRP-XL
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Figure 3 | Inhibition or deletion of Cx40 reduces platelet inside-out signalling and granule secretion. The effect of 40Gap27 on 1mgml 1 CRP-XL- (a),
10mM ADP- (b) and 0.1 Uml 1 thrombin- (c) induced ﬁbrinogen binding was measured by ﬂow cytometry using human PRP. Similarly, ﬁbrinogen binding
to Cx40þ /þ and Cx40 / mouse platelets was measured using whole blood following stimulation with 1 mgml 1 CRP-XL (d). Fibrinogen binding
obtained with vehicle or Cx40þ /þ was taken as 100%. Human PRP was stimulated with 1 mgml 1 CRP-XL (e), 10mM ADP (f) and 0.1 Uml 1 thrombin
(g) in the presence and absence of 40Gap27 (100mgml 1) and the level of P-selectin exposed on surface measured by ﬂow cytometry. Similarly, P-Selectin
exposure upon stimulation with 1 mgml 1 CRP-XL using whole blood obtained from Cx40þ /þ and Cx40 / was measured (h). P-selectin exposure
with vehicle or Cx40þ /þ was taken as 100%. Human washed platelets were stimulated with 0.5 mgml 1 CRP-XL in the presence and absence of
40Gap27 (100mgml 1), and the level of ATP secretion was measured using lumino-aggregometry (i,j). Data represent mean±s.d. (n¼4; Student’s t-test,
*Po0.05, **Po0.01 and ***Po0.001).
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(1 mgml 1) was measured in the presence or absence of 40Gap27
(100 mgml 1) using human platelet-rich plasma (PRP). This was
reduced by B40% in the presence of 40Gap27 (100 mgml 1;
Fig. 3e). Reduced platelet granule secretion was also observed
upon stimulation of human platelets with ADP (10 mM; Fig. 3f) or
thrombin (0.1Uml 1; Fig. 3g). Similarly, P-selectin exposure on
Cx40 / mouse platelets was reduced upon stimulation with
1 mgml 1 CRP-XL in comparison with Cx40þ /þ mouse plate-
lets (Fig. 3h).
The observed effects of Cx40 inhibition or deletion on
individual platelets analysed by ﬂow cytometry (ﬁbrinogen
binding and P-selectin exposure; Fig. 3a–h) point towards the
importance of Cx40 hemichannels in platelet activation.
To assess the effects of Cx40 inhibition on dense granule
secretion, the consequences of 40Gap27 treatment of human
washed platelets on ATP secretion was assessed. CRP-XL
(0.5mgml 1) induced ATP release was inhibited by B40% with
40Gap27 (100 mgml 1; Fig. 3i,j). Together, these data suggest that
Cx40 has an important role in granule secretion.
The effects of Cx40 are not solely secretion dependent. To
assess whether diminished platelet activation during Cx40
blockade is due solely to the reduced levels of granule secretion
and secondary activators of platelet function, CRP-XL-induced
ﬁbrinogen binding was measured in the presence of apyrase,
an enzyme that hydrolyses the ADP and the TXA2 synthesis
blocker indomethacin (through inhibition of cyclooxygenase).
Addition of a saturating concentration of apyrase (4Uml 1) in
PRP reduced the ﬁbrinogen binding to 70% when stimulated
with CRP-XL (0.5 mgml 1; Fig. 4a). Similarly, addition of
indomethacin at a saturating concentration of 20mM reduced
the ﬁbrinogen binding by B80% upon CRP-XL (0.5 mgml 1)
stimulation (Fig. 4a). The addition of both apyrase (4Uml 1)
and indomethacin (20 mM) reduced the ﬁbrinogen binding
level byB85% with CRP-XL (0.5 mgml 1; Fig. 4a). An increased
concentration of CRP-XL (1 mgml 1) resulted in a similar
level of inhibition at the same concentration of apyrase and
indomethacin (Fig. 4b). Addition of 40Gap27 (100 mgml 1)
along with 4Uml 1 apyrase or 20mM indomethacin or
both, resulted in a further reduction in ﬁbrinogen-binding
levels (Fig. 4c,d) at lower and higher concentration of
CRP-XL, indicating that the inhibitory effects of 40Gap27
on platelet functions are not solely due to defects in secreted ADP
or the synthesis of TXA2. Consistent with these data, the inhi-
bition of Cx40 or Cx37 with 40Gap27 or 37,43Gap27
(100 mgml 1), respectively, or the deletion of either connexin in
mouse platelets did not affect the level of TXB2 (a stable TXA2
metabolite) synthesized in platelets after platelet activation by
CRP-XL (Fig. 5).
Cx40 functions independently from Cx37. As connexins may
form homomeric or heteromeric hemichannels, we sought to
determine whether Cx40 and Cx37 function independently on
platelets. The speciﬁcity of action of 40Gap27 or 37,43Gap27
was ﬁrst conﬁrmed to establish a lack of inhibitory effect on
Cx40- and Cx37-deﬁcient mouse platelets, respectively (Fig. 2j
and Fig. 6a,b). 40Gap27 (100 mgml 1) inhibited CRP-XL-sti-
mulated (1 mgml 1) ﬁbrinogen binding (Fig. 7a) and P-selectin
exposure (Fig. 7b) in Cx37 / mouse platelets to a similar extent
to that observed in Cx37þ /þ platelets. Similarly, 37,43Gap27
(100 mgml 1) inhibited ﬁbrinogen binding (Fig. 7c) and
P-selectin exposure (Fig. 7d) in Cx40 / mouse platelets to a
similar level as that observed on Cx40þ /þ platelets. Together,
these data demonstrate that both Cx37 and Cx40 are able to
contribute to platelet regulation independently.
Cx40 is important for clot retraction. We have shown previously
that gap junctions contribute to intercellular communication and
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Figure 4 | Inhibitory effects of 40Gap27 on platelet function are not solely due to defects in granule secretion or TXA2 synthesis. The level of
ﬁbrinogen binding was measured in the presence and absence of apyrase (4Uml 1) or indomethacin (20mM), or both (at the same concentration) on 0.5
(a) and 1mgml 1 (b) CRP-XL activation in human PRP. The level of ﬁbrinogen binding obtained in the absence of apyrase or indomethacin was taken as
100%. Similarly, 0.5 (c) and 1mgml 1 (d) CRP-XL-induced ﬁbrinogen binding was measured in the presence or absence of 40Gap27 (100mgml 1)
in addition to apyrase (4Uml 1) and/or indomethacin (20 mM). The level of ﬁbrinogen binding obtained in the absence of 40Gap27 (but in the presence of
apyrase and/or indomethacin) was taken as 100% to compare the inhibitory levels obtained with 40Gap27. Data represent mean±s.d. (n¼ 3;
Student’s t-test, *Po0.05 and **Po0.01). A, apyrase; C, control; G, 40Gap27; I, indomethacin.
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the coordination of clot retraction17. As observed for general gap-
junction blockers and 37,43Gap27 (ref. 17), 40Gap27 did not alter
the initial clot formation but reduced clot retraction threefold at
90min (Fig. 8a,b). Clot retraction was reduced to a similar extent
in Cx40 / compared with Cx40þ /þ mouse platelets (Fig. 8c,d).
These data suggest that inhibition of Cx40-mediated intercellular
signalling reduces outside-in signalling through integrin aIIbb3,
which drives clot retraction.
Cx40 regulates haemostasis in mice. To analyse the physio-
logical importance of Cx40 for haemostasis, tail-bleeding assays
were performed on mice. Mice were anaesthetized intraper-
itoneally and tail tips were transected to observe the bleeding
time. Cx40þ /þ mice bled for 199 s (between 175 and 219 s)
compared with the Cx40 / mice that bled for 657 s (between
309 and 1,200 s; Fig. 8e). Similarly, wild-type mice were treated
either with scrambled control peptide or 40Gap27 (at an esti-
mated circulating concentration of 100 mgml 1) for 3min before
transection of the tail tip. Control peptide-treated mice bled for
175 s (between 150 and 199 s), whereas 40Gap27-treated mice
bled for 279 s (between 205 and 363 s; Fig. 8f). These data toge-
ther suggest that Cx40 has a signiﬁcant role in the maintenance of
haemostasis.
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were measured in Cx37 / (b) and Cx40 / (c) mouse platelets upon stimulation with 1 mgml 1 CRP-XL. The levels of TXB2 obtained in human
platelets were shown as concentrations. The levels of TXB2 obtained with resting platelets in Cx37
þ /þ or Cx40þ /þ mouse platelets were taken as 100%
for comparison with Cx37- or Cx40-deﬁcient mouse platelets. R, resting platelets. Data represent mean±s.d. (n¼ 3; Student’s t-test was used for statistical
analysis).
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Figure 6 | 37,43Gap27 does not affect Cx37 / platelets conﬁrming its
selectivity. Platelet aggregation performed in the presence or absence of
37,43Gap27 (100mgml 1) using washed platelets obtained from Cx37þ /þ
(a) and Cx37 / (b) mice was recorded for 180 s following stimulation
with CRP-XL (0.5mgml 1). The level of aggregation obtained in the
absence of 37,43Gap27 was taken as 100%. Data represent mean±s.d.
(n¼ 3; Student’s t-test, *Po0.05).
100
80
60
40
20
0
100
80
60
40
20
0
0 100 0 100
40Gap27 (μg ml–1)
0 100 0 100
40Gap27 (μg ml–1)
100
80
60
40
20
0 100 0 100
37,43Gap27 (μg ml–1)
0 100 0 100
37,43Gap27 (μg ml–1)
Cx37 +/+ Cx37 –/– Cx37 +/+ Cx37 –/–
Cx40 +/+ Cx40 –/– Cx40 +/+ Cx40 –/–
**
** **
*
Fi
br
in
og
en
 b
in
di
ng
 (%
)
Fi
br
in
og
en
 b
in
di
ng
 (%
)
P-
se
le
ct
in
 (%
)
P-
se
le
ct
in
 (%
)
0
100
80
60
40
20
0
*
*
* *
a b
c d
Figure 7 | Cx40 regulates platelet function independently from Cx37.
The levels of ﬁbrinogen binding (a) and P-selectin exposure (b) in
Cx37þ /þ and Cx37 / mouse platelets in the presence or absence of
40Gap27 (100mgml 1) were measured by ﬂow cytometry using whole
blood following stimulation with 1 mgml 1 CRP-XL. Similarly, the levels of
ﬁbrinogen binding (c) and P-selectin exposure (d) in Cx40þ /þ and
Cx40 / mouse platelets in the presence or absence of 37,43Gap27
(100mgml 1) were measured following stimulation with 1 mgml 1 CRP-
XL. The level of ﬁbrinogen binding obtained in the absence of inhibitor was
taken 100%. Data represent mean±s.d. (n¼ 4; Student’s t-test, *Po0.05
and **Po0.01).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3564
6 NATURE COMMUNICATIONS | 4:2564 | DOI: 10.1038/ncomms3564 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
Discussion
A previous study16 described the presence of Cx37 as the only
connexin expressed in platelets, where the effects of general
inhibitors were attributed to the function of this connexin alone.
We have, however, reported the presence of multiple connexins and
the effects of non-selective connexin inhibitors and Cx37 deﬁciency
on platelet function17. The present ﬁndings broaden the repertoire
of platelet connexins that participate in platelet function to Cx40.
Inhibition of Cx40 with a selective peptide inhibitor resulted in
reduction in platelet functions such as ﬁbrinogen binding,
aggregation and granule secretion, similar to the effects observed
with the inhibition of Cx37, indicating activatory roles for both
Cx40 and Cx37 in platelet function. These conclusions are
supported by similar observations using mouse platelets that lack
either connexin. The inhibitory effects observed with 40Gap27 in
the presence of apyrase and indomethacin suggest that the effects of
Cx40 blockade on platelet aggregation are not solely due to reduced
granule secretion or TXA2 synthesis. Further experiments using a
Cx40 inhibitor on Cx37 / platelets and Cx37 inhibitor on
Cx40 / platelets suggest that these connexins are able to function
independently from each other. Consistent with this observation,
we have failed to demonstrate heterotypic interactions between
Cx40 and Cx37 through co-immunoprecipitation experiments. The
inhibitory effects of 40Gap27 on haemostasis, mirrored in the
phenotype of Cx40 / mice, indicate the physiological importance
of Cx40 in the maintenance of haemostasis.
These data together with our previous study suggest that the
hemichannels may have key roles in the initial activation of
platelets when they are in isolation, although the nature of
the signals conveyed by the hemichannels are yet to be
established. We have previously demonstrated that within a
platelet thrombus, gap junctions form between the cells, to enable
sustained contact-dependent signalling to control thrombus
stability and clot retraction17. It is possible, therefore, that
following platelet stimulation, as aggregates begin to form, both
hemichannel and gap junctions between platelets may be
important, with the latter representing a new communication
paradigm for the propagation of initial activatory signals between
platelets. The roles of other platelet connexins such as Cx32 and
Cx43 in platelet function remain to be explored. It is possible that
these connexins may also control activatory mechanisms in
platelet function working independently from each other, or in
combination with other family members.
Further work is required to determine the nature of
hemichannel- and gap-junction-dependent signalling events that
regulate platelet activation and clot retraction, and to determine
whether connexins on platelets mediate functional interactions
with other cells in the vasculature in health and disease. A priority
will be to identify the nature of the signalling molecules that are
conveyed by platelet hemichannels or gap junctions. Under-
standing of the molecular mechanisms that regulate their
conductance will be crucial to explore therapeutic (anti-
thrombotic) potential.
Methods
Platelet preparation and aggregation. Human platelet preparation and aggre-
gation assays were performed using standard methods17,21,22. Brieﬂy, blood was
obtained from aspirin-free, healthy human volunteers with written informed consent
as approved by the University of Reading Research Ethics Committee. PRP was
prepared by centrifuging the blood for 20min at 102 g at room temperature for ﬂow
cytometry assays. Washed platelets were prepared by further centrifuging the PRP
with PGI2 (125ngml 1) at 1,413 g for 10min at room temperature and resuspended
in modiﬁed Tyrodes-HEPES buffer (134mM NaCl, 2.9mM KCl, 0.34mM
Na2HPO4.12H2O, 12mM NaHCO3, 20mM HEPES and 1mM MgCl2, pH 7.3) to
the ﬁnal density of 4 108 cells per ml for aggregation assays. Contaminating blood
cells were counted by light microscopy and were mainly erythrocytes; leukocytes
were rarely encountered with total cell contaminant level ofo1 per 13,000 platelets.
Aggregation assays were performed by light transmission aggregometry using CRP-
XL (a selective agonist for platelet collagen receptor GPVI, from Professor R Farndale
(University of Cambridge, UK)), thrombin or ADP (Sigma Aldrich, UK) in the
presence or absence of various concentrations of gap-junction inhibitors. 37,43Gap27
(SRPTEKTIFII; Sigma Aldrich) and 40Gap27 (SRPTEKNVFIV; Anaspec, USA) were
used as selective inhibitors for Cx37 and Cx40, respectively. Scrambled peptides
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Figure 8 | Cx40 regulates clot retraction and haemostasis. The effect of 40Gap27 on clot retraction using human PRP was analysed in vitro for 90min
(a,b). The effect of Cx40 deﬁciency on clot retraction was analysed (c,d). Data represent mean±s.d. (n¼4; Student’s t-test, *Po0.05 and **Po0.01).
Deletion of Cx40 or the effect of 40Gap27 (estimated plasma concentration: 100 mgml 1) on haemostasis in mice was analysed by measuring the
bleeding time after tail tip excision. The bleeding time obtained with Cx40 / mice were compared with Cx40þ /þ mice (e). Similarly, the bleeding time
obtained with scrambled peptide- (estimated 100mgml-1) treated group was compared with 40Gap27-treated mice (f). Data represent mean±s.d. (n¼ 5
for Cx40þ /þor Cx40 / mice and n¼ 5 mice for scrambled peptide control or 40Gap27 treated). The signiﬁcance between control and treated groups,
and P-values (as shown) were calculated by non-parametric Mann–Whitney test using GraphPad Prism.
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IPFVESKRTVN and REKIITSFIPT were used as negative controls for 40Gap27 and
37,43Gap27, respectively.
Dense granule secretion and immunoblotting. ATP secretion assays were per-
formed using luciferin–luciferase luminescence substrate (Chrono-log, USA) by
luminescence aggregometry17. The level of ATP secreted from washed platelets on
stimulation with agonists such as CRP-XL in the presence and absence of 40Gap27
was measured by observing the level of luminescence liberated. SDS–PAGE and
immunoblotting were performed using standard protocols17,23,24. Cx40 antibodies
(used at a dilution of 1:1,000) were obtained from Chemicon, USA. Rabbit anti-
human 14-3-3z (1:2,000) or GAPDH (glyceraldehyde 3-phosphate dehydrogenase;
1:1,000; Santa Cruz Biotechnology, USA) were used to detect 14-3-3z or GAPDH
to ensure equivalent levels of protein loading in immunoblots. The secondary
antibodies for immunoblotting: Cy5 goat anti-rabbit IgG (1:1,000) and Cy3 goat
anti-mouse IgG (1:1,000) antibodies were obtained from Invitrogen, UK.
Mouse blood collection and platelet preparation. Colonies of Cx40 /
(refs 25,26) and Cx37 / (refs 27,28) mice were maintained on a C57BL6 genetic
background, and littermate controls were used in all experiments. All animals were
used following approval from the University of Reading Local Ethics Review Panel
and license from the British Home Ofﬁce. Mice were killed and the blood was
collected immediately by cardiac puncture into a syringe containing ACD (2.5%
sodium citrate, 2% D-glucose and 1.5% citric acid; at 1 (ACD):9 (blood) ratio) for
aggregation assays. Similarly, the blood was collected into syringe containing 4%
citrate (at 1 (citrate):9 (blood) ratio) for ﬂow cytometry and clot retraction assays. The
blood was centrifuged at 203 g for 8min and PRP collected into fresh tubes. After
addition of PGI2 (12.5ngml 1), the PRP was further centrifuged at 1,028 g for 5min.
The resultant platelet pellet was resuspended in modiﬁed Tyrodes-HEPES buffer. The
platelets were rested for 30min before aggregation assays were performed.
Flow cytometry. CRP-XL-stimulated ﬁbrinogen binding and P-selectin exposure
were measured in human PRP using ﬂuorescein isothiocyanate (FITC)-labelled
rabbit anti-human ﬁbrinogen antibodies (Dako UK Ltd) and mouse anti-human
CD62P antibody (BD Biosciences, UK), respectively, in the presence or absence of
different concentrations of respective inhibitors. Platelets were incubated with
inhibitor or control for 3min before activation with CRP-XL for 20min at room
temperature. The cells were then ﬁxed in 0.2% (v/v) formyl saline before analysis by
ﬂow cytometry. Similarly, various receptor expression levels were measured on
mouse platelets using FITC-conjugated antibodies for GPVI, integrin aIIbb3,
integrin a2b1 and GPIba obtained from Emfret Analytics (Germany). To measure
the level of P-selectin exposure on mouse platelets, FITC-conjugated P-selectin
antibody (Emfret Analytics) was used. Data were analysed by calculating the
median ﬂuorescence intensity.
Clot retraction. Human or mouse PRP (200 ml) was mixed with 5 ml of red blood
cells, and vehicle or gap-junction inhibitor (as needed), and the ﬁnal volume raised
to 1ml with modiﬁed Tyrodes-HEPES buffer. Fibrin clot formation was initiated
by adding thrombin (1Uml 1). Clot retraction around a glass capillary added
before clot formation was observed over a period of 90min at room temperature.
Clot weight was measured as a marker for clot retraction at different time points.
Assessment of haemostasis. Experiments were performed in live mice with
approval from the University of Reading Local Ethical Review Panel and British
Home Ofﬁce. C57BL/6 mice (7–8 weeks old; The Jackson Laboratory, UK) were
anaesthetized using ketamine (80mg kg 1) and xylazine (5mg kg 1) adminis-
tered via the intraperitoneal route 20min before the experiment and placed on a
heated mat. 40Gap27 (estimated 100mgml 1 of blood based on the weight of
mouse) or scrambled peptide control was injected via femoral vein 5min before
1mm of tail tip was removed using a scalpel blade, and the tail tip was placed in
sterile saline at 37 C. The time to cessation of bleeding was measured up to 10min.
Similarly, Cx40þ /þ and Cx40 / mice were anaesthetized and tail tip was
removed before measuring the bleeding time.
TXB2 assay. TXB2 assays were performed using a TXB2 immunoassay kit obtained
from Enzo Lifesciences (UK) and following the manufacturer’s protocols. Brieﬂy,
human or mouse PRP was prepared and stimulated with agonists such as CRP-XL in
the presence or absence of gap-junction inhibitors (as needed). The samples were
centrifuged at 13,000 g for 10min after aggregation to remove platelets and frozen until
required. The levels of TXB2 in plasma samples were calculated using standard curves.
Statistical analysis. The data obtained from aggregation, ﬁbrinogen binding,
granule secretion and clot retraction assays were analysed using Student’s t-test.
Median ﬂuorescence intensity values obtained in ﬁbrinogen binding and granule
secretion assays were converted into percentage for comparison of controls with
inhibited samples. The tail-bleeding assay data were analysed using the non-para-
metric Mann–Whitney test using GraphPad Prism (version 5.04) from GraphPad
Software Inc.
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